In simple terms
When a doctor tells you abnormal cells were found 'in situ', it means they are sitting precisely where they formed and have not spread into neighbouring tissues. Think of your tissue like a room with solid walls: the abnormal cells are inside the room, but the walls are completely intact. Because these cells have not broken through the protective border, they cannot reach your bloodstream or lymph nodes. While they require careful monitoring or removal so they do not become invasive later, they are caught at the earliest possible stage.
Key takeaways
- 'In situ' means abnormal cells remain confined to their original cell layer.
- The basement membrane remains intact, preventing cells from entering the bloodstream.
- In situ conditions are classified as Stage 0 cancer.
- They are highly treatable and do not metastasise in this state.
Definition
In clinical pathology, 'in situ' refers to neoplastic cells that exhibit structural and behavioural features of malignancy under microscopic evaluation but remain strictly demarcated by an intact basement membrane. The basement membrane is a thin, dense sheet of extracellular matrix that separates epithelial tissues from underlying connective tissue, blood vessels, and lymphatic channels.
Because cells in situ have not breached this protective barrier, they lack access to the circulatory and lymphatic systems. As a consequence, true in situ lesions are biologically incapable of distant metastasis. Although commonly classified as Stage 0 cancer, many pathologists and clinicians consider them pre-invasive lesions or pre-cancers rather than true invasive disease.
Why it matters
Finding lesions in situ represents the ideal scenario for early cancer detection. It provides an opportunity to treat or remove abnormal tissue before it transforms into invasive cancer capable of spreading. Because the risk of regional or distant spread is practically zero at this stage, treatments are typically less aggressive, often requiring only local surgical removal or specialised topical therapies rather than intensive systemic chemotherapy. Discussing an in situ diagnosis helps patients understand that their condition is highly treatable and carries an exceptional prognosis.
Related biomarkers and tests
In situ lesions are diagnosed through microscopic examination of tissue obtained by biopsy or surgical resection. Routine screening tests like mammograms (detecting microcalcifications), Pap smears, colonoscopies, and skin examinations often detect these lesions before symptoms appear. No specific molecular biomarker defines 'in situ' beyond structural histology.
Related cancers
In situ lesions occur in epithelial tissues throughout the body. The most common examples are ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) in the breast. It also appears in cervical intraepithelial neoplasia (CIN 3/carcinoma in situ), melanoma in situ, and non-muscle invasive bladder cancer (carcinoma in situ).
Related treatments
Management focuses on local control to prevent progression to invasive cancer. Treatments include surgical excision with clear margins (such as lumpectomy), topical immunomodulators for skin lesions, or intravesical therapy like BCG for bladder carcinoma in situ. Chemotherapy is not indicated, though hormonal therapy may be recommended for ER-positive breast DCIS.
Frequently asked questions
Is carcinoma in situ considered true cancer?
Carcinoma in situ is classified as Stage 0 cancer or non-invasive cancer. While the cells look like cancer cells under a microscope, they have not invaded deeper tissue or spread. Some clinicians view it as pre-cancerous, requiring treatment to prevent invasive disease.
Can an in situ lesion spread to other organs?
No, an in situ lesion cannot spread to other organs. Because it has not penetrated the basement membrane, the abnormal cells cannot reach blood vessels or lymphatic channels, making distant metastasis biologically impossible whilst the condition remains strictly in situ.
Does having an in situ diagnosis require chemotherapy?
No, systemic chemotherapy is not used for in situ lesions. Because there is no risk of circulating tumour cells, treatment focuses purely on local management, such as surgical removal, radiation therapy, or occasionally topical or hormone-blocking treatments depending on the organ affected.
References
- 1.NCI Dictionary of Cancer Terms: Carcinoma in situ— National Cancer Institute
- 2.Breast Cancer: Ductal Carcinoma In Situ (DCIS)— American Society of Clinical Oncology (Cancer.Net)
- 3.WHO Classification of Tumours: Principles of Staging— World Health Organization
Ask GetOnco AI
Get personalised answers about In Situ — Non-Invasive, Pre-Cancerous Cell Changes from your AI cancer care coordinator.
- Can you explain In Situ — Non-Invasive, Pre-Cancerous Cell Changes in simple words?
- What does In Situ — Non-Invasive, Pre-Cancerous Cell Changes mean for my treatment plan?
- What questions should I ask my oncologist about In Situ — Non-Invasive, Pre-Cancerous Cell Changes?
- What next steps do you recommend regarding In Situ — Non-Invasive, Pre-Cancerous Cell Changes?
GetOnco AI provides educational information and never replaces advice from your medical team.
Explore related topics
More in this section
Glossary terms in this article
Last reviewed August 1, 2026
Medical disclaimer
Educational information only. GetOnco is software, not a medical provider, and does not diagnose disease or recommend treatments. Always discuss your situation with qualified healthcare professionals.